Drug schedules in Canada: PDL, CDSA, NAPRA, BC and Quebec

Drug schedules in Canada

Drug schedules in Canada are not one list. Federal law decides whether a drug needs a prescription: Health Canada's Prescription Drug List (PDL) and the Controlled Drugs and Substances Act (CDSA). Provinces then decide where and how it is sold.

Most provinces use NAPRA's National Drug Schedules: Schedule I (prescription), Schedule II (pharmacist only), Schedule III (pharmacy self-selection) and Unscheduled. British Columbia and Quebec use provincial versions, as shown in NAPRA's implementation table.

"Schedule 1 drugs Canada" can mean NAPRA Schedule I (prescription drugs) or CDSA Schedule I (including opioids, cocaine and methamphetamine). BC Schedule I and Schedule 1 of the Controlled Substances Regulations are other possibilities. Schedule 2 and Schedule 3 have the same overlap across NAPRA, the CDSA, BC and the CSR. Always name the system.

The Prescription Drug List

The PDL is the federal prescription drugs list. It names the medicinal ingredients that make a drug prescription-only, unless a qualifier says otherwise. It has two parts, human use and veterinary use, and it replaced Schedule F to the Food and Drug Regulations on 19 December 2013. Controlled substances and radiopharmaceuticals are not on it.

Read the full qualifier, not just a dose threshold. On the human-use list, omeprazole and esomeprazole have non-prescription exceptions for frequent heartburn: 20 mg daily for 14 days. But a non-prescription exception does not mean unrestricted retail sale.

Federal prescription status applies across Canada. For a federally non-prescription drug, a province can allow general sale or require pharmacy sale, pharmacist intervention or a prescription.

The PDL changes in three ways, per Health Canada's amendment process. The Prescription Drug Status Committee recommends, and the Director General of the Pharmaceutical Drugs Directorate decides.

• A routine addition comes with a new market authorization. It takes effect at once, with a notice of amendment and no consultation.
• A special addition moves a non-prescription drug to prescription. It needs a 75-day consultation, then a notice of intent (the transition is usually 6 months or more), then a notice of amendment.
• A switch from prescription to non-prescription also needs a 75-day consultation and a notice of intent. Removal follows 6 months later.

Health Canada posts changes on its notices page. Melatonin was amended in June 2026: it is prescription-only when sold for sleep-related use in children and adolescents under 18. Nicotine buccal pouches with 4 mg or less per unit do not need a prescription and are regulated as natural health products (notice of 14 January 2026).

Two other schedules in the Food and Drugs Act also appear in the DPD. Schedule C covers radiopharmaceuticals. Schedule D covers biologics such as insulin, immunizing agents, blood-derived drugs and monoclonal antibodies. Schedule F to the Act is empty. It's a different thing from the old Schedule F to the Regulations, which ended in 2013.

CDSA schedules for controlled substances

The Controlled Drugs and Substances Act uses schedule numbers I to IX, with VII and VIII repealed:

Cannabis left Schedule II in 2018. It's now regulated under the Cannabis Act, which also repealed Schedules VII and VIII.

Controlled substances are outside the PDL on purpose. CDSA drugs still need a prescription under the controlled-substance regulations, now the CSR, so a human drug's full prescription-only status is the PDL plus the CDSA schedules.

Those regulations changed on 1 October 2026, the commencement date in section 239 of the Controlled Substances Regulations (SOR/2025-242). The CSR replaced the Narcotic Control Regulations (NCR), the Benzodiazepines and Other Targeted Substances Regulations (BOTSR), and Parts G and J of the Food and Drug Regulations. It has four schedules of its own: 1 Narcotics, 2 Controlled Drugs, 3 Targeted Substances and 4 Restricted Drugs. A companion amendment, SOR/2025-243, corrected and restated entries in CDSA Schedules I, III, IV and VI from the same date. Schedule VI precursors still fall under the Precursor Control Regulations. Older guidance that cites the NCR, the BOTSR or Part G is now out of date.

NAPRA National Drug Schedules

NAPRA's schedules set the conditions of sale in pharmacies:

• Schedule I: prescription needed. The pharmacist supplies the drug after a practitioner's diagnosis and intervention.
• Schedule II: no prescription, but the pharmacist must step in at the sale. The drug is kept where only the pharmacist can sell it.
• Schedule III: sold from the self-selection area of a pharmacy, with a pharmacist available.
• Unscheduled: sold in any retail outlet with no professional supervision.

NAPRA assesses each drug in a cascade: Schedule I factors first, then II, then III. A drug that meets none is Unscheduled. PDL and CDSA drugs appear in NAPRA Schedule I for information only, and where they conflict, the PDL and CDSA win.

A recent example: from 27 January 2026, acetaminophen and ibuprofen combinations are Schedule II above 20,000 mg acetaminophen or 6,000 mg ibuprofen per package. At or under both limits they are Schedule III.

Provincial drug schedules

NAPRA says each province applies its schedules "in a slightly different manner". Its implementation table shows three models. Eight provinces and three territories (AB, MB, NB, NL, NS, ON, PE, SK, NT, NU, YT) adopt NAPRA by reference. BC uses NAPRA plus provincial approval. Quebec keeps its own schedules.

Ontario is the typical by-reference case. O. Reg. 264/16 points to the NAPRA list, so NAPRA changes apply automatically. The Ontario College of Pharmacists defines Schedule III as self-selection in the professional products area within 10 m (30 ft) of the dispensary, and Ontario calls unscheduled drugs Schedule U.

BC drug schedules

BC's Drug Schedules Regulation (B.C. Reg. 9/98) includes an extra prescription category, Schedule IA. It covers drugs in the triplicate or duplicate prescription program, such as hydromorphone, methadone, morphine and oxycodone.

Schedule I is prescription-only. Schedule II requires pharmacist sale from the Professional Service Area, without public access. Schedule III permits self-selection in the Professional Products Area. Drugs in these schedules, including IA, must be sold from licensed pharmacies. Unscheduled drugs may be sold by non-pharmacists.

BC dropped its old Schedule IV, "prescription by pharmacist", on 19 June 2023. Since 17 July 2025, a drug on the PDL or NAPRA lists that isn't already in a BC schedule is deemed to be in the matching BC schedule. Exclusions include antiprogestins (such as mifepristone), prostaglandins (such as misoprostol), ephedrine, naloxone, nicotine, pseudoephedrine, semaglutide, sex hormones and vaccines. For those, read the BC entry itself. Naloxone for opioid overdose, for instance, is Schedule II nationally but unscheduled in BC. Single-ingredient pseudoephedrine is BC Schedule II, while pseudoephedrine combination products and single-dose levonorgestrel emergency contraception are Schedule III.

Quebec

Quebec doesn't use the NAPRA model. Under the Pharmacy Act, the Office des professions sets annexes to the Regulation respecting the terms and conditions for the sale of medications. Per the Office's procedure document, Annexe I covers human prescription drugs, Annexe II drugs sold "sous contrôle pharmaceutique", and Annexe III drugs sold "sous surveillance pharmaceutique". Annexes IV and V cover animal drugs. A drug on no annex can be sold anywhere. A drug removed from the federal PDL goes into Annexe II automatically.

How a drug's schedule shows in the DPD

Health Canada's Drug Product Database has a "Schedule(s)" search filter. Its terminology page lists Prescription, Non-Prescription drugs, Ethical, Narcotics, Controlled Drugs, Targeted Substances, Schedule C and Schedule D. "Ethical" means no federal prescription requirement, but generally prescribed, such as MRI contrast agents and hemodialysis solutions. Prescription Recommended and CDSA Recommended indicate pending listings.

Where several categories apply, the DPD shows the most stringent. Narcotics map to CDSA Schedules I or II, Controlled Drugs to I, III or IV, and Targeted Substances to I or IV. The page predates the CSR, so its references to the NCR, the BOTSR and Part G point to repealed rules.

For bulk work, the data extracts include schedule.txt (marketed), schedule_ap.txt (approved), schedule_ia.txt (cancelled) and schedule_dr.txt (dormant). The Read Me describes the table, QRYM_SCHEDULE, with fields DRUG_CODE and SCHEDULE.

The DPD's schedule field shows federal status, not NAPRA, BC or Quebec categories. A "Non-Prescription drugs" product can still fall under NAPRA Schedule II or III. You'll need the provincial list too, which is a nuisance when you're checking dozens of products.

RegAffairs AI has a cited answer on Canada's drug schedules that links each point to its source.